Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKNA Ikena Oncology	$1.27 +0.8%	$1.29	$0.97 ▼ $1.94	$61.29M	0.5	131,235 shs	259,644 shs
INZY Inozyme Pharma	$4.00	$3.76	$0.72 ▼ $6.24	$258.25M	2.27	953,803 shs	N/A
MREO Mereo BioPharma Group	$1.77 -0.6%	$2.46	$1.57 ▼ $5.02	$281.43M	0.46	1.35 million shs	2.37 million shs
TVRD Tvardi Therapeutics	$24.61 +2.6%	$0.00	$8.13 ▼ $34.31	$230.35M	0.2	68,722 shs	28,374 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKNA Ikena Oncology	0.00%	-7.97%	-6.62%	+11.40%	-23.49%
INZY Inozyme Pharma	0.00%	0.00%	+0.25%	+308.41%	-24.95%
MREO Mereo BioPharma Group	0.00%	+9.94%	-37.89%	-24.03%	-54.38%
TVRD Tvardi Therapeutics	0.00%	-9.99%	-4.50%	+2,460,999,900.00%	+2,460,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKNA Ikena Oncology	2.8094 of 5 stars	3.3	3.0	0.0	0.0	2.0	1.7	1.3
INZY Inozyme Pharma	2.8906 of 5 stars	4.2	4.0	0.0	0.0	0.0	2.5	0.0
MREO Mereo BioPharma Group	1.8108 of 5 stars	3.6	1.0	0.0	0.0	2.3	1.7	0.0
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKNA Ikena Oncology	2.50	Moderate Buy	$3.00	136.22% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	306.78% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	161.07% Upside

Current Analyst Ratings Breakdown

Latest IKNA, MREO, TVRD, and INZY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKNA Ikena Oncology	$9.16M	6.69	N/A	N/A	$2.61 per share	0.49
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
MREO Mereo BioPharma Group	$10M	28.14	N/A	N/A	$0.39 per share	4.54
TVRD Tvardi Therapeutics	$7.14M	32.26	N/A	N/A	($3.02) per share	-8.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKNA Ikena Oncology	-$49.23M	-$0.86	N/A	N/A	N/A	N/A	-30.59%	-27.55%	8/14/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest IKNA, MREO, TVRD, and INZY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IKNA Ikena Oncology	-$0.14	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	IKNA Ikena Oncology	-$0.21	-$0.18	+$0.03	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKNA Ikena Oncology	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKNA Ikena Oncology	N/A	13.31	13.31
INZY Inozyme Pharma	0.65	2.19	2.19
MREO Mereo BioPharma Group	N/A	8.92	8.92
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKNA Ikena Oncology	75.00%
INZY Inozyme Pharma	88.30%
MREO Mereo BioPharma Group	62.83%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
IKNA Ikena Oncology	5.94%
INZY Inozyme Pharma	12.18%
MREO Mereo BioPharma Group	5.50%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKNA Ikena Oncology	70	48.26 million	45.39 million	Not Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

IKNA, MREO, TVRD, and INZY Headlines

Recent News About These Companies

Raymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform Recommendation

July 15, 2025 | msn.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | finance.yahoo.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | businesswire.com

Cantor Fitzgerald Predicts TVRD FY2025 Earnings

July 15, 2025 | americanbankingnews.com

Tvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James Financial

July 14, 2025 | marketbeat.com

Tvardi Therapeutics (NASDAQ:TVRD) Research Coverage Started at Cantor Fitzgerald

July 14, 2025 | americanbankingnews.com

Equities Analysts Offer Predictions for TVRD FY2025 Earnings

July 14, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight Recommendation

July 12, 2025 | msn.com

Tvardi Therapeutics (NASDAQ:TVRD) Earns Overweight Rating from Analysts at Cantor Fitzgerald

July 11, 2025 | marketbeat.com

Tvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 2.4% - What's Next?

July 11, 2025 | marketbeat.com

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKNA, MREO, TVRD, and INZY Company Descriptions

Ikena Oncology NASDAQ:IKNA

$1.27 +0.01 (+0.79%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.27 0.00 (0.00%)

As of 04:02 AM Eastern

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Mereo BioPharma Group NASDAQ:MREO

$1.77 -0.01 (-0.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 06:13 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Tvardi Therapeutics NASDAQ:TVRD

$24.61 +0.63 (+2.63%)

As of 07/18/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time